Ajetunmobi Olabayo H, Badali Hamid, Romo Jesus A, Ramage Gordon, Lopez-Ribot Jose L
Department of Molecular Microbiology & Immunology, South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX, USA.
Glasgow Biofilm Research Network, School of Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8TA, UK.
Biofilm. 2023 Apr 23;5:100126. doi: 10.1016/j.bioflm.2023.100126. eCollection 2023 Dec.
Virtually all species linked to clinical candidiasis are capable of forming highly resistant biofilms on different types of surfaces, which poses an additional significant threat and further complicates therapy of these infections. There is a scarcity of antifungal agents, and their effectiveness, particularly against biofilms, is limited. Here we provide a historical perspective on antifungal agents and therapy of biofilms. As we reflect upon the past, consider the present, and look towards the future of antifungal therapy of biofilms, we believe that there are reasons to remain optimistic, and that the major challenges of biofilm therapy can be conquered within a reasonable timeframe.
几乎所有与临床念珠菌病相关的物种都能够在不同类型的表面上形成高度耐药的生物膜，这构成了额外的重大威胁，并使这些感染的治疗更加复杂。抗真菌药物稀缺，而且它们的有效性，尤其是对生物膜的有效性有限。在此，我们提供了关于抗真菌药物和生物膜治疗的历史观点。当我们回顾过去、审视现在并展望生物膜抗真菌治疗的未来时，我们相信有理由保持乐观，并且生物膜治疗的主要挑战能够在合理的时间范围内被攻克。
